Background: Hepatitis C is a common infectious disease in thalassemic patients due to repeated blood transfusion. More than 85% of HCV-infected individuals develop chronic hepatitis, of which 25% may result in liver cirrhosis, hepatic failure or hepatocellular carcinoma. In thalassemic patients hepatic damage due to HCV infection is aggravated by transfusion iron overload. Materials and methods: In this clinical trial, 81 thalassemic patients were studied for evidence of HCV infection and response to α-IFN. Routine tests of transfusion transmitted infections were HBs Ag, HBs Ab, HIV Ab, and HCV Ab. Those revealed to have positive HCV Ab were tested for HCV-RNA by PCR. Liver function tests including SGOT, SGPT, PT, PTT were also checked. Liver biopsy was performed for those patients who had liver enzyme elevation. Recombinant α-IFN, 3 million units trice weekly, was administered for infected patients with positive HCV-RNA. HCV-RNA was checked 6 and 12 months later, whereas liver enzymes were checked every 3 months. Results: 22 patients had positive HCV Ab and 17 had positive HCV-RNA. In 8 patients, liver enzymes were increased, so liver biopsy was achieved. Their histological examination revealed mild chronic hepatitis (4 patients), chronic active hepatitis (3 patients), and severe hemosidrosis (2 patients). 12 patients received α-IFN for one year. In 7 patients (58%), after one year treatment, HCV-RNA became negative. HCV-RNA was checked 6 months after discontinuing treatment in 7 patients, which was negative in 5 patients. 2 patients relapsed. Conclusion: This study shows that clearance of serum HCV-RNA can be obtained by a prolonged course of treatment with α-IFN in thalassemic patients. Response rate is similar to non thalassemic patients, but with lower relapse rate.